Mechanistic Evaluation of Siplizumab (MEDI-507) Activity On Normal and Malignant T-Lymphocytes" (Abstract 2504, presented in a poster session, "Lymphoma: Pre-Clinical -- Chemotherapy and Biologic Agents," on Sunday, Dec.
In 2003, the company filed INDs for Numax(TM), a potential next-generation antibody targeting respiratory syncytial virus; an anti-IL-9 antibody targeting asthma; and siplizumab, an antibody targeting CD2 for T-cell lymphoma.
This patent rights agreement follows licenses granted to MedImmune in 1997 under Protein Design's antibody humanization patents for Synagis (palivizumab), the first monoclonal antibody approved to prevent an infectious disease, and for siplizumab, an antibody currently in Phase II testing as a treatment for psoriasis.
Revamped AlloMune System Development Strategy: The company revised its clinical development strategy for the AlloMune System and will now employ kits consisting of BioTransplant's proprietary antibody MEDI-507, also known as siplizumab, in combination with products that have already been approved in the United States.
MedImmune's research and development organization is advancing and expanding the focus of a number of internal product candidates through melanoma and prostate cancer studies with Vitaxin, non-small cell lung cancer and acute myelogenous leukemia (AML) studies with Ethyol, and T cell lymphoma studies with siplizumab.
In 2002, the company completed several late-stage clinical trials, including Phase 2 clinical trials with siplizumab, and the Phase 3 Synagis clinical trial in congenital heart disease patients that led to approval of an expanded indication by the U.
Revamped AlloMune Development Strategy: BioTransplant is revising its clinical development strategy for the AlloMune System, employing kits consisting of siplizumab in combination with products that have already been approved in the United States.